Abstract Number: 13L • 2017 ACR/ARHP Annual Meeting
Significant, Sustained Improvement in Knee Function after Intra-Articular TPX-100: A Double-Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2 Trial
Background/Purpose: The current Phase 2 study was designed to evaluate safety, tolerability and preliminary efficacy of TPX-100 by IA administration in subjects with mild to…Abstract Number: 14L • 2017 ACR/ARHP Annual Meeting
Miv-711, a Novel Cathepsin K Inhibitor Demonstrates Evidence of Osteoarthritis Structure Modification: Results from a 6 Month Randomized Double-Blind Placebo-Controlled Phase IIA Trial
Background/Purpose: The need for drugs that achieve structure modification in OA is imminent but their development has been burdened by the need for large, long…Abstract Number: 15L • 2017 ACR/ARHP Annual Meeting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee
Background/Purpose: CR845 is a selective kappa opioid receptor agonist with a peripheral mechanism of action. Here we report preliminary results from a Phase 2b study…Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting
Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…Abstract Number: 17L • 2017 ACR/ARHP Annual Meeting
Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study
Background/Purpose: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has shown significant and rapid efficacy in psoriatic arthritis (PsA). We present primary results…Abstract Number: 18L • 2017 ACR/ARHP Annual Meeting
Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis
Background/Purpose: RITAZAREM (ClinicalTrials.gov: NCT01697267) is an international, randomized, controlled trial comparing rituximab with azathioprine as maintenance therapy after induction of remission with rituximab and glucocorticoids…Abstract Number: 1 • 2017 ACR/ARHP Annual Meeting
Anti-Phosphatidylserine/Prothrombin Antibodies (aPS/PT) As Potential Diagnostic Markers and Risk Predictors of Venous Thrombosis and Obstetric Complications in Antiphospholipid Syndrome
Background/Purpose: , Methods: , Results: and Conclusion: Background/Purpose:The antiphospholipid syndrome (APS) is a thrombophilic disorder characterized by clinical manifestations of vascular thrombosis and obstetric complications…Abstract Number: 2 • 2017 ACR/ARHP Annual Meeting
Identifying “Second Hit” Risk Factor(s) Associated with Thrombosis and Pregnancy Morbidity in Ethnically Diverse Antiphospholipid Antibodies Positive Patients
Background/Purpose: The evaluation of thrombotic and pregnancy risks associated with antiphospholipid antibodies (aPL) in individual patients without APS clinical manifestation is challenging. Our aim is…Abstract Number: 3 • 2017 ACR/ARHP Annual Meeting
Burden of Antiphospholipid Syndrome in a Thromboembolic Disease Registry
Background/Purpose: Prevalence of antiphospholipid antibodies in general population has been reported in about 5%. Impact of different thrombophilias in clinical thromboembolic disease is difficult to…Abstract Number: 4 • 2017 ACR/ARHP Annual Meeting
Downregulation of microRNAs in Plasmacytoid Dendritic Cells Is Associated with a Type I Interferon Signature in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Background/Purpose: The most prominent alteration in the immune system of patients with SLE is a type I interferon (IFN) signature, which we recently also reported…Abstract Number: 5 • 2017 ACR/ARHP Annual Meeting
Clinical Utility of the Global Antiphospholipid Syndrome Score (GAPSS) for Risk Stratification: A Pooled Analysisfrom 2273 Patients
Background/Purpose: Recently, our group conceived a risk score for clinical manifestations of APS [the global APS score or GAPSS] that takes into account the combination…Abstract Number: 6 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years Long-Term Observation
Background/Purpose: The goal of this long-term project was to investigate the course of pregnancy in patients with APS (primary or secondary with SLE) in 1993-2017,…Abstract Number: 7 • 2017 ACR/ARHP Annual Meeting
Predictive Value for Thrombosis of Double or Triple Positivity in Secondary APS Depends on the Component Assays and the Type of Thrombosis
Background/Purpose: The lupus anticoagulant (LAC) is individually the antiphospholipid antibody (aPL) most associated with thrombotic risk in both primary and secondary APS. Anticardiolipin (aCL) and…Abstract Number: 8 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Leukocytes Demonstrate Increased Adhesive Potential: a Search for Novel Therapeutic Targets
Background/Purpose: Adhesion of leukocytes to the endothelium is an initiating event in the thrombosis inherent to antiphospholipid syndrome (APS). Over the years, a number of…Abstract Number: 9 • 2017 ACR/ARHP Annual Meeting
Renal Protective Effect of Antiplatelet Therapy in Antiphospholipid Antibody-Positive Lupus Nephritis Patients without the Antiphospholipid Syndrome
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. Since antiphospholipid syndrome (APS) is…
ACR Meeting Abstracts